Vienna, Austria, January 27^th: EUCODIS Bioscience is glad to announce that it has teamed up with Tube Pharmaceuticals to bring the production of tubulysins to a commercial level. Tube Pharmaceuticals and EUCODIS now jointly produce and commercialize tubulysin A and B and other variants of this cytotoxic compound.

Tubulysins are isolated from the culture broth of strains of Archangium gephyra and Angiococcus disciformis, both members of a Gram negative, soil-dwelling group of bacteria known as myxobacteria. The production process has been up-scaled and tubulysin A and B are now produced by EUCODIS Bioscience.

Novel Enzymatic, 1-Step Site-Specific Protein Conjugation Technology for ADC Production

Berlin, Germany, and Vienna, Austria, April 19^th: ProBioGen AG, a leading specialist for contract development and manufacturing of complex glycoproteins and EUCODIS Bioscience, an expert in enzyme engineering, today jointly announced the signature of an exclusive license agreement on C-LiNK (CTAT), an innovative, site-specific ADC conjugation technology. Under the agreement ProBioGen gains exclusive rights to commercialize EUCODIS’ enzymatic C-terminal linking technology, and to offer it, together with its antibody development services, royalty-free to ADC-developing parties.